These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24860149)

  • 21. Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice.
    Moriya J; Wu X; Zavala-Solorio J; Ross J; Liang XH; Ferrara N
    J Vasc Surg; 2014 May; 59(5):1402-9.e1-4. PubMed ID: 23856609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
    Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of embryonic lung vascular development by vascular endothelial growth factor receptors, Flk-1 and Flt-1.
    Yamamoto Y; Shiraishi I; Dai P; Hamaoka K; Takamatsu T
    Anat Rec (Hoboken); 2007 Aug; 290(8):958-73. PubMed ID: 17654674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VEGF is major stimulator in model of choroidal neovascularization.
    Kwak N; Okamoto N; Wood JM; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3158-64. PubMed ID: 10967078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF-induced angiogenesis.
    Chai J; Jones MK; Tarnawski AS
    FASEB J; 2004 Aug; 18(11):1264-6. PubMed ID: 15180964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic osmotic stimuli increase salusin-beta-like immunoreactivity in the rat hypothalamo-neurohypophyseal system: possible involvement of salusin-beta on [Ca2+]i increase and neurohypophyseal hormone release from the axon terminals.
    Saito T; Dayanithi G; Saito J; Onaka T; Urabe T; Watanabe TX; Hashimoto H; Yokoyama T; Fujihara H; Yokota A; Nishizawa S; Hirata Y; Ueta Y
    J Neuroendocrinol; 2008 Feb; 20(2):207-19. PubMed ID: 18047553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue plasminogen activator and plasminogen are critical for osmotic homeostasis by regulating vasopressin secretion.
    Imamura Y; Morita S; Nakatani Y; Okada K; Ueshima S; Matsuo O; Miyata S
    J Neurosci Res; 2010 Jul; 88(9):1995-2006. PubMed ID: 20175210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation.
    Yamaoka-Tojo M; Ushio-Fukai M; Hilenski L; Dikalov SI; Chen YE; Tojo T; Fukai T; Fujimoto M; Patrushev NA; Wang N; Kontos CD; Bloom GS; Alexander RW
    Circ Res; 2004 Aug; 95(3):276-83. PubMed ID: 15217908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.
    Takahashi T; Yamaguchi S; Chida K; Shibuya M
    EMBO J; 2001 Jun; 20(11):2768-78. PubMed ID: 11387210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release.
    van Mil A; Grundmann S; Goumans MJ; Lei Z; Oerlemans MI; Jaksani S; Doevendans PA; Sluijter JP
    Cardiovasc Res; 2012 Mar; 93(4):655-65. PubMed ID: 22227154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype.
    Ortéga N; Jonca F; Vincent S; Favard C; Ruchoux MM; Plouët J
    Am J Pathol; 1997 Nov; 151(5):1215-24. PubMed ID: 9358746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells.
    Kowarik M; Onofri C; Colaco T; Stalla GK; Renner U
    Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):113-20. PubMed ID: 19373754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.